CleanTech Lithium PLC (CTL) — Investment Research Note

Executive summary

CleanTech Lithium is a pre-revenue AIM-listed lithium exploration and development company advancing two brine projects in Chile (Laguna Verde and Viento Andino) using Direct Lithium Extraction ("DLE") technology, powered by renewable energy. Over the period covered, the company has progressed technical work — JORC resource upgrade to 1.63Mt LCE, DLE pilot plant operation, battery-grade lithium carbonate production at 99.78% purity — while suffering severe operational/financial setbacks including going-concern doubts, multiple deeply dilutive placings (IPO at 30p → 22p → 16p → 11p → 5p), CEO resignation under undisclosed-loan circumstances, and CEOL application rejection (later overcome by acquiring 97% licence coverage). The single most important point for valuation today is that the agreement of CEOL terms (March 2026) is a transformational gate, but the equity remains hostage to ~US$35m of deferred consideration to vendors, convertible loan notes at a 6p strike, and a multi-hundred-million-dollar construction-finance gap that will almost certainly require a strategic partner and further substantial dilution.

Fair value estimate

Methodology: Risked NAV based on the Laguna Verde Scoping Study (Jan 2023) 2024-05 final results / 2023-09 interim.

Key assumptions:

• Scoping Study post-tax NPV₈ of US$1.83bn at long-term LCE price of US$22,500/t
• Risking factor 3–7% to reflect scoping-stage (pre-PFS), pre-permitted, pre-financed project with heavy execution risk, deferred consideration of US$35m, convertible loan notes (~£3m), and inevitable future equity dilution to fund US$~400m construction capex
• Per-share basis: ~122.7m shares in issue post Aug-25 placing 2025-08 placing results, with heavy overhang from warrants and loan-note conversion at 6p
• GBP/USD ~1.27

Calculation:

• Risked NPV: US$1.83bn × 4% = US$73m ≈ £58m attributable today, less ~£15m deferred consideration NPV and ~£3m convertible loan notes = £40m
• Range: 3% risking = £25m equity; 6% risking = £75m equity
• Per current share count: 5p – 30p per share
• Implied market cap range: £6m – £37m
• Mid: ~15p / £18m

Comparison to disclosed market cap of £15.3m: Mid fair value is broadly in line, but the range is wide and the upside case requires both CEOL ratification and strategic-partner emergence on non-punitive terms. Absolute upside/downside vs current: –60% to +140%, centred near zero.

Sector context

• Sector classification: Basic Resources / Basic Materials — confirmed. Sub-sector: lithium exploration & development.
• Quality/growth/leverage profile: Below typical sector peers. Pre-revenue, going-concern qualified, heavy dilution history. Better-resourced lithium peers (Albemarle, SQM, Pilbara, Liontown) have lower execution risk; closer comps among Chilean DLE-juniors are Lithium Chile, Atlas Lithium, Galan Lithium.
• Listed peers: Lithium Chile (TSXV:LITH), Galan Lithium (ASX:GLN), Atlas Lithium (NASDAQ:ATLX).

Investment thesis (3 bullets)

1. CEOL is now agreed in principle — the single biggest de-risking event in CTL's history; with 97% licence coverage post-Minergy acquisition and final ratification pending, the project has a path to commercialisation that was uncertain only a year ago 2026-04-30 updated investor presentation; 2025-08-11 acquisition announcement.
2. DLE pilot plant has demonstrably produced 99.78% pure battery-grade lithium carbonate — process risk meaningfully reduced; samples can now be sent to potential offtakers for product qualification, supporting future strategic-partner discussions 2025-06-12 final results; 2025-09 interim.
3. Scoping Study economics are very robust at long-term lithium prices — post-tax NPV₈ of US$1.83bn versus current market cap of £15m implies massive optionality if (and it is a large "if") permitting, partnering and financing all fall into place 2024-05 annual report; 2023-05 final results.

Key risks (3 bullets)

1. Going-concern and dilution risk — auditor flagged material uncertainty regarding going concern 2025-06-12 final results; cash of £143k at Jun-25 2025-09 interim required a £5m August raise at just 5p, and loan-note holders have a 6p conversion right plus an Event-of-Default step-in right if cash falls below £1m in Jersey 2025-08-11 fundraising announcement.
2. Deferred consideration overhang — US$35m payable to Laguna Verde licence vendors (US$10.5m fixed over 5 years, US$24.5m on production milestones or 10th anniversary) creates a substantial real liability on a £15m market-cap company 2025-06-12 final results, note 16.
3. Construction-finance gap — Scoping Study capex of US$384m has no funding path; even with strategic partner participation, dilution of existing shareholders into a Final Investment Decision is virtually certain, and there is no firm offtake or strategic deal as of the latest filings 2025-09 interim outlook.

Operating leverage

CTL is pre-revenue, so traditional operating-leverage analysis does not apply. Looking forward to the modelled commercial phase from the Scoping Study: operating cost of US$3,875/t LCE versus long-term price of US$22,500/t implies an ~83% cash gross margin at steady-state production of 20,000tpa LCE, which is very high operating leverage to lithium price. With largely fixed processing/mining infrastructure once built, a 10–20% lithium price upside would translate to a significantly larger uplift to operating profit. However: this is theoretical — none of this leverage is captured by today's equity holders unless the project clears CEOL ratification, EIA, DFS, FID and ~US$400m construction financing. At the current stage, incremental cash inflows are dilutive equity, not operating margin. I score operating leverage low (around 30) on a realistic current-business basis, not on the theoretical future producer basis.

Value-trap signals

• Sequential equity raises at progressively lower prices: IPO 30p (Mar-22) → 47p (Oct-22) → 22p (Nov-23) → 16p (Feb-25) → 11p (Oct-24) → 5p (Aug-25), with each round bringing fresh warrants at a discount multiple placing announcements
• CEO resignation under undisclosed share-pledge circumstances (Apr-25), with subsequent disclosure he had ceased to own shares 2025-06-12 final results, subsequent events
• Four directors stepped down in August 2025 as part of cost-cutting and operational restructuring 2025-09 interim
• CEOL application rejected in April 2025 (later overturned via licence acquisition) — disclosure quality and execution have been imperfect
• Going-concern material uncertainty flagged in auditor's report 2025-06-12 final results
• Llamara project impaired in full (£0.5m) after suboptimal results 2025-06-12 final results
• Repeated reinterpretation of accounting treatment for loan notes (Dec-24 restatement of H1-24 interim results) 2024-12-31 CEOL & amended interim results
• Heavy warrant overhang: ~34.5m warrants outstanding at Jun-25, plus 86m placee warrants from Aug-25 raise 2025-09 interim

Earnings vs. expectations

CTL is pre-revenue and does not publish forward earnings guidance or attract analyst consensus EPS, so traditional beat/meet/miss tracking is not possible. On a milestone-execution basis, however: ASX listing was repeatedly delayed (initially Q4 2024, slipped to Q1/Q2 2025, then paused entirely 2025-09 interim); the first CEOL application was rejected in April 2025 2025-06-12 final results; the planned production timeline has slipped from "2025/2026" at IPO to "no firm date" currently. The pattern is one of repeated guidance slippage and undershooting on timing, with technical milestones (resource upgrade, DLE pilot) broadly delivered.

Conviction

Conviction rating: 2 (low)

Anchoring factors: (i) the Scoping Study NPV is the only credible quantitative valuation anchor, and it is itself low-confidence (pre-PFS); (ii) PFS has been "well advanced" but is awaiting CEOL clarity, leaving the central assumption set unverified; (iii) the share count, dilution path and ultimate equity recovery are highly uncertain.

Limiting factors: (i) wide gap between theoretical project NPV (~£1.4bn) and current market cap (£15m) reflects compounded risk that is genuinely difficult to risk-weight; (ii) the path between today and first lithium revenue involves at least three further large equity events (Australian listing, strategic partner, construction finance), each at unknown terms.

Driver scoring rationale

• AI beneficiary: lithium is a battery material; only the very loosest argument links it to AI via grid-scale BESS for data-centre power, but value capture is by lithium price, not the company-specific story. This is a commodity exposure, not an AI-receiver play.
• Operating leverage: high in theory at the modelled producer state, low in reality at current pre-revenue stage with continual dilution.
• Valuation: discount to risked NPV exists but is justified by extreme stage-of-development risk.
• Quality / downside protection: weak — going-concern flag, repeated dilution, deferred consideration overhang, departed CEO, restructured board.

For a portfolio explicitly seeking AI-receiver exposure with operating leverage and valuation discipline plus acceptable downside protection, CTL fails on multiple dimensions: no AI angle, pre-revenue with no current operating leverage, valuation only attractive on heroic NPV-realisation assumptions, and balance-sheet fragility precludes "acceptable downside protection."